Skip to main content
. 2020 Jan 14;10:1278. doi: 10.3389/fgene.2019.01278

Figure 1.

Figure 1

Upregulation of miR-221/222 in the cisplatin-resistant TNBC. (A) A miRNA screening identified 31 upregulated miRNAs and 21 downregulated miRNAs with fold change ≥ 2 in MDA-MB-231-R (cisplatin-resistant) cells compared to MDA-MB-231-S (cisplatin-sensitive) cells. (B) Validation of the sensitivity to cisplatin of MDA-MB-231-R and MDA-MB-231-S cells by 48h-treatment with 20 μM cisplatin. (C) Validation of the upregulation of miR-221 and miR-222 in MDA-MB-231-R cells. (D) TCGA database showed higher level of miR-221 and miR-222 in the cisplatin/carboplatin-resistant breast cancer patients (n = 3) compare to -sensitive patients (n = 7). Values are equal to mean ± SEM. *p < 0.05, **p < 0.01.